AntriaBio is a biopharmaceutical company that develops novel extended release therapies by combining proprietary formulation and manufacturing capabilities with well-known molecules to significantly improve standards of care. AntriaBio's lead product candidate is AB101, an injectable once-weekly basal insulin for type 1 and type 2 diabetes that addresses a $11 billion market where the current standard of care is a once-daily basal insulin injection.
AntriaBio’s development strategy is to:
AB101 is an example of this approach. The benefits of long-acting insulin and early insulin initiation in patients with diabetes are well-recognized. The AB101 formulation utilizes the concept of differential reactivity for amidation to produce PEGylated insulin. As part of this process, various factors are critical and controlled, including the chain length of the PEG as well as the site of conjugation. These and other factors are optimized to produce an active pharmaceutical without degrading physiological activity. We employ rational design strategies for our formulations - including AB101 - to produce microspheres with superior characteristics for injection and that are designed to optimize manufacturing yields in a highly reproducible process.